203 related articles for article (PubMed ID: 34922144)
1. Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.
Mainguene J; Basse C; Girard P; Beaucaire-Danel S; Cao K; Brian E; Grigoroiu M; Gossot D; Luporsi M; Perrot L; Vieira T; Caliandro R; Daniel C; Seguin-Givelet A; Girard N
Lung Cancer; 2022 Jan; 163():51-58. PubMed ID: 34922144
[TBL] [Abstract][Full Text] [Related]
2. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
3. Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer.
Scherpereel A; Martin E; Brouchet L; Corre R; Duruisseaux M; Falcoz PE; Giraud P; Le Péchoux C; Wislez M; Alifano M
Lung Cancer; 2023 Mar; 177():21-28. PubMed ID: 36682142
[TBL] [Abstract][Full Text] [Related]
4. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
5. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection.
Tanner NT; Gomez M; Rainwater C; Nietert PJ; Simon GR; Green MR; Silvestri GA
J Thorac Oncol; 2012 Feb; 7(2):365-9. PubMed ID: 22237260
[TBL] [Abstract][Full Text] [Related]
6. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
[TBL] [Abstract][Full Text] [Related]
7. A nomogram to predict the survival of stage IIIA-N2 non-small cell lung cancer after surgery.
Mao Q; Xia W; Dong G; Chen S; Wang A; Jin G; Jiang F; Xu L
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1784-1792.e3. PubMed ID: 29554790
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of skip N2 metastases in stage IIIA non-small cell lung cancer].
Liu K; Chen HL; You QS; Huang JF; Wang H
Ai Zheng; 2009 Jul; 28(7):725-9. PubMed ID: 19624899
[TBL] [Abstract][Full Text] [Related]
9. Role of surgery in N2 NSCLC: pros.
Shien K; Toyooka S
Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
[TBL] [Abstract][Full Text] [Related]
10. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
Duan H; Liang L; Xie S; Wang C
BMC Cancer; 2020 Aug; 20(1):809. PubMed ID: 32847544
[TBL] [Abstract][Full Text] [Related]
11. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
12. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
[TBL] [Abstract][Full Text] [Related]
13. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
[TBL] [Abstract][Full Text] [Related]
15. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
[TBL] [Abstract][Full Text] [Related]
16. Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
Ma Q; Liu D; Guo Y; Shi B; Song Z; Tian Y
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):342-8. PubMed ID: 20677562
[TBL] [Abstract][Full Text] [Related]
17. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
Han H; Zhao Y; Gao Z; Zheng D; Fu F; Zhao Z; Tang Y; Xiang J; Sun Y; Hu H; Chen H
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2115-2122. PubMed ID: 31175463
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
[TBL] [Abstract][Full Text] [Related]
19. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
[TBL] [Abstract][Full Text] [Related]
20. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
